Multiple Myeloma Clinical Trial

Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma

Summary

This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adequate bone marrow function
eGFR ≥ 30 mL/min
Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
Serum calcium (corrected for albumin) at or below the ULN range

Exclusion Criteria:

Candidate for treatment regimens known to provide clinical benefit in MM
Active infection requiring parenteral anti-infective treatment
Any medical or psychiatric condition which in the opinion of the investigator or Teneobio Medical Monitor places the subject at an unacceptably high risk for toxicities, could interfere with successful or safe delivery of therapy, or could interfere with evaluation of the investigational product or interpretation of subject safety

Study is for people with:

Multiple Myeloma

Study ID:

NCT04453397

Recruitment Status:

No longer available

Sponsor:

TeneoOne Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Wake Forest
Winston-Salem North Carolina, 27157, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Study ID:

NCT04453397

Recruitment Status:

No longer available

Sponsor:


TeneoOne Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider